Genetic Signatures Limited (GSS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and thank you for joining Genetic Signatures Investor Webinar today. I am Stella Maurice of Monsoon Communications. In today's webinar, Genetic Signatures will share their healthier results and latest developments. Joining us are CEO Alison Rossiter and CFO Carl Packman to brief you on the details. Before we begin, I would like to highlight that you can submit questions using the Q&A function and we will get to them after the presentation. Similar questions might be grouped and would be answered at once. I will now hand over to Alison to begin. Good afternoon, everybody. It gives me great pleasure today to announce our first half of 2025 market update. Starting with the highlights, our sales come in at a triple digit 136% improvement over the former half of 2024. This is predominantly due to strong respiratory season across Australia, a comeback after the flu B issue that we suffered last year, and some great UK progress with our enteric panels. Another positive message around our gross margin has also increased from 42% up to 59%. And our underlying loss is at a 20% improvement. So the three key figures there are all going in the right direction, which we're very, very proud to announce today. We do have a loss of 15.2 million recorded statutory loss. But that does include the 6.8 million impairment, which we'll speak about on the next few slides. We're in a strong cash position. We'll speak about that later too. And in terms of the 6.8 million impairment, we've gone through a strategic assessment of the technology landscape to make sure that we are bringing the best automated solution to market at a reduced cost and at a faster speed for the market. And we'll speak about that on the next slide too. And finally, I think the thing that everyone's been...